Introduction
Peroxisomes are single-membrane-bound organelles present in virtually all eukaryotic cells. They contain more than 50 matrix proteins that participate in a variety of metabolic pathways speci®c to the peroxisome [1] . Disorders of the peroxisome are divided broadly into two groups: single enzyme disorders and defects of peroxisomal biogenesis (see Table 1 ). The latter group of disorders has contributed directly to our understanding of protein importation into the peroxisome. By combining the study of cells obtained from patients with advances in molecular genetics speci®cally in yeast, peroxisome assembly and the mechanism of disease is being solved. The other group of disorders, the single protein disorders, is dominated by X-linked adrenoleukodystrophy, which is by far the most common of these diseases. New information on the genetics and clinical features of this highly variable disorder is coming into focus.
Peroxisome protein importation and assembly
The assembly of the peroxisome requires the interaction of a set of biogenesis proteins (peroxins), which are encoded by PEX genes [2] . Peroxisomal matrix proteins are synthesized on free polyribosomes and need to be directed to the peroxisome. There are two types of peroxisome targeting signals (PTS), PTS1 and PTS2. The majority of proteins destined for the peroxisome use PTS1, which consists of a terminal tripeptide (SKL) that is recognized by the soluble receptor Pex5p. PTS2 consists of a nine-residue signal located at the Nterminus. It directs the import of a smaller number of proteins using the soluble receptor Pex7p. Both receptors bind their targeting sequence in the cytoplasm and the receptor-peptide complex dock at the peroxisome surface via membrane-associated complexes containing other peroxisome assembly proteins: Pex3p, Pex13p, Pex14p, and Pex17p. Other peroxins function later in the process and are implicated in the translocation. These other peroxins are zinc-binding proteins acting downstream of the docking complex, and are postulated to constitute the translocation complex involved in matrix protein import.
This import method has no parallel with any other organelle. Initially, it was believed that peroxisomes would be similar to other subcellular components in their biogenesis and protein importation. Mitochondria and other organelles have a signal receptor system to direct polypeptides to the translocation machinery (translocon) at the surface of the target organelle. The polypeptide is then threaded through the channel component of the translocon with the aid of a molecular chaperone in an unfolded conformation. With this system, a single translocon can accommodate many polypeptides of diverse size while maintaining the critical membrane permeability barrier. The peroxisome is very different. Walton et al.
[3] demonstrated that peroxisome import allows the uptake of folded oligomerized proteins or even the import of non-PTS-containing substances as long as it was with PTS-containing cargo [4 . . ].
Dammai and Subramani [5 . . ] examined Pex5p, the receptor for PTS1, and determined further differences from other receptor transporter systems. There had been con¯icting evidence about the location of this receptor, and at least two models had been put forward to explain the discrepancy. The ®rst considered was a typical, simple shuttle model with Pex5p delivering its target to the peroxisome and then the release of the receptor for another round back to the cytosol. A different model had also been put forward, unique and more complicated, but that better explained the con¯icting ®ndings. The extended shuttle model predicts that after docking at the surface, Pex5p remains bound to the peptide and is translocated into the matrix along with the cargo. Upon reaching the matrix, it is released and the receptor transported back into the cytosol where it would be available to undergo another round. Dammai and Subramani [5 . . ], using a variety of approaches, demonstrated that Pex5p is indeed translocated into the peroxisome and is capable of returning as predicted.
In addition to the targeting of matrix proteins using one of the two PTS signals, there is a third mechanism for the peroxisomal importation of peroxisomal membrane proteins (PMP). Jones et al. [6 . ] examined PMP34 and found that it contained at least two targeting regions. Examining another PMP, PEX13, the authors again found that it had multiple, non-overlapping targeting signals. These and other PMP did not share targeting regions. Unlike the previously described targeting sequences for matrix proteins, these PMP sequences were relatively long and contained at least one membrane-spanning domain. They hypothesized that PEX19 interacted with the binding domains and was necessary for targeting and incorporation into the peroxisomal membrane. Others have also demonstrated a role for PEX19 in binding PMP, and it has been speculated that it acts as a chaperone rather than as a receptor [7] .
Molecular basis of peroxisome assembly disease
The initial work on understanding peroxisomal disease was performed using complementation studies; 12 different groups were subsequently identi®ed, and in 11 of these the defective gene is known. The majority of the groups contain individuals with PTS1 disorders, only one group with PEX7 defects consists of PTS2 defects and has all of the individuals with rhizomelic chondrodysplasia punctata [1].
Complementation group 1 (CG1) is the largest, characterized by mutations in PEX1, a gene coding for a 143 000 M r AAA protein. Approximately 65% of peroxisomal assembly patients belong to this group. The clinical phenotype covers a relatively wide spectrum of severity, from Zellweger syndrome to the milder neonatal adrenoleukodystrophy and infantile Refsum disorders. Analysis of mutations reveals two relatively common alleles in the PEX1 gene: one allele with a missense mutation (G843D) associated with a milder phenotype and a second with a 1 basepair insertion resulting in a premature stop codon at amino acid 740. This insertion tends to be seen in individuals with more severe disease [8 . . ].
Walter et al. [8 . . ] used single-strand con®rmation polymorphism analysis to evaluate a series of patients belonging to CG1 for mutations in PEX1, and studied phenotype±genotype correlations. Two groups of patients could be demonstrated within CG1. The ®rst group showed a clear relationship between genotypes that were null alleles with no evidence of PEX1 protein, and the second group of mutations allowed some residual function of the PEX1 protein. The majority of these more mildly affected patients with protein expression had a G843D mutation in at least one of their alleles. There was some ability to characterize the presence of residual or absent protein with clinical presentation. It was still not possible to make reliable predictions regarding the prognosis of the more mildly affected patients on the basis of the protein levels themselves or from other routinely determined biochemical data. The clinical utility of routine DNA mutational analysis is uncertain, as are the less routine protein importation measures on ®broblasts.
It is still not known which of the resultant enzymatic de®ciencies causes disease, but studies on knockout mice are beginning to provide some answers. Infants with Zellweger syndrome have a characteristic neuronal migration defect. A similar defect is found in mice lacking the import receptor for peroxisomal matrix proteins, Pxr1 mice. Gressens et al. [9] analysed Pxr17/7 mice, and showed that the migration defect was caused by altered N-methyl-D-aspartate glutamate receptor-mediated calcium mobilization. This N-methyl-D-aspartate receptor dysfunction was linked to a de®cit in platelet-activating factor, secondary to the peroxisome impairment [9] . Tatsumi et al. [10] found increased levels of gangliosides in ®broblasts of patients with Zellweger syndrome. It is not known if this was a primary or secondary event, but abnormalities of gangliosides would be expected to have implications in brain development.
Adrenoleukodystrophy X-linked adrenoleukodystrophy, the most common peroxisomal disorder, results from a defect in the peroxisomal beta oxidation of very long chain fatty acids (VLCFA) [11] . These saturated fatty acids accumulate in all tissues of the body, but the effects of the disease are primarily manifested in the myelin of the central nervous system, adrenal cortical cells, and the Leydig cells of the testes. The diagnosis of adrenoleukodystrophy can be made directly in males by the use of VLCFA analysis. This is a reliable test in affected males, but in females the false negative rate is at least 20% of individuals. In these circumstances, the use of focused DNA analysis has enabled diagnosis to be made. Extended family screening can be performed, and it has been argued that given the relatively low incidence of new mutations (approximately 5%), it should be undertaken in newly diagnosed individuals and their families [12] .
Given the defect in VLCFA metabolism, it was originally presumed that the defect would be an initial enzymatic step, but after localization and characterization, it was instead determined to be a portion of an adenosine triphosphate binding cassette (ABC) transmembrane protein. The proteins in this group transport a wide variety of ligands in both eukaryotic and prokaryotic cells. The typical ABC transporter has two hydrophilic nucleotide-binding folds and two hydrophobic transmembrane domains. The adrenoleukodystrophy protein (ALDP) contains only one hydrophobic and one hydrophilic domain, and is designated a half-transporter. This is not a unique situation and three other mammalian peroxisomal ABC half-transporters have been identi®ed, PMP70, adrenoleukodystrophy-related protein (ALDR) an autosomal recessive product, and PMP69 [11] .
Adrenoleukodystrophy mutations have been identi®ed in all patients in whom the entire gene has been examined. Over 400 mutations have been reported, and the majority of kindreds have private mutations with over half (68.5%) non-recurring. Mutations are now recorded in an international registry and may be reviewed at www.x-ald.nl. Mutations are spread throughout the entire gene, but one mutational hotspot at exon 5 has been noted. A recurrent dinucleotide deletion AG 1414/1416 has been reported in 12% of all reported kindreds. Haplotype analysis in 12 of these kindreds has established that the kindreds are unrelated. The AG deletion results in a frameshift at amino acid residue E471 and a premature stop codon at position 554. The predicted protein lacks the nucleotide-binding fold and is probably inactive [13±15].
A role for ALDP in VLCFA beta oxidation has been demonstrated by experiments in which the overexpression of ALDP, PMP70 and ALDR can restore VLCFA beta oxidation in ®broblasts from adrenoleukodystrophy patients. Unterrainer et al. [16] demonstrated that restoration was more effective in affected cells that were ALDP-de®cient compared with ®broblasts expressing mutated ALDP. The non-functional endogenous protein acted in a dominant negative fashion. This obviously has implications for gene therapy trials because approximately 30% of patients appear to make a recognizable protein [16] .
The phenotypic variability of adrenoleukodystrophy is broad and includes at least six distinct clinical presentations in males. These phenotypes are distinct in the age of presentation, neuropathology, and the rate of progression. The wide variation of clinical presentation within families has been commented on extensively, and it is known that there is no apparent genotype±phenotype correlation. It is also known that adrenal involvement does not correlate with neurological disease. Adrenomyeloneuropathy and childhood onset cerebral adrenoleukodystrophy accounts for approximately 80% of cases. In the childhood cerebral form, a severe, rapid demyelination occurs and appears to be secondary to an in¯ammatory reaction associated with the accumulation of VLCFA in myelin lipids. Early symptoms include behavioral changes, attention de®cits, impairment of vision and hearing, and then later spasticity, dementia, seizures, progressing relatively quickly to a vegetative state and death. Adrenomyeloneuropathy may actually be the more common phenotype [17 . . ]. In adrenomyeloneuropathy, myelopathy and neuropathy are the predominant ®ndings, and appear to be secondary to axonal degeneration and secondary demyelination. Symptoms include spastic paraparesis, bowel and bladder symptoms, and sensory disturbances in the legs. Progression is typically stated to be slow, but the presence of cerebral demyelination in some individuals has been reported. Other phenotypes include an adolescent and adult onset cerebral disease without evidence of spinal cord involvement, adrenal insuf®ciency without neurological involvement, and those individuals with only a biochemical defect.
Beyond the childhood form of the disease, little was known about the evolution of phenotypes in adrenoleukodystrophy. Adrenomyeloneuropathy was often stated to be slowly progressive, and the implication was that individuals who escaped the childhood form of the disease would at worst develop this`benign' form. van Geel et al. [17 . . ] assessed 129 men over a period of 10.1+5 years. Among 32 men who were originally neurologically asymptomatic, 50% developed neurological symptoms. In 68 adrenomyeloneuropathy patients initially without cerebral ®ndings, 19% developed cerebral demyelination during the evaluation period. Most of the patients with cerebral phenotypes deteriorated, and the rate of progression to a vegetative state or death was comparable to the childhood form of the disease. The results indicated that there is a relatively high risk for men with the biochemical defect of adrenoleukodystrophy to develop neurological de®cits and for adrenomyeloneuropathy patients to develop cerebral demyelination. Axonal degeneration and cerebral demyelination emerged independently of each other. Although it has been hypothesized that there are genetic modi®ers that determine variation, this work indicated that cerebral involvement does occur eventually in a substantial proportion of adrenomyeloneuropathy individuals who do not have these ®ndings at diagnosis. Whether this variation in the occurrence of cerebral disease re¯ects genetic modi®ers awaits demonstration. Other possible modi®ers besides genetic include immunological variation as well as environmental factors; however, explanations need to account for different phenotypes being reported in identical twins [18] .
The other important recent ®nding in adrenomyeloneuropathy was the study by Powers and colleagues [19, 20] , which examined lumbar dorsal root ganglia. No neuronal loss, necrosis, or apoptosis, nor obvious atrophy was demonstrated. Morphometric studies showed neuronal atrophy with a decrease in the number of large neurons and a corresponding increase in smaller neurons (52000 mm 2 ). On ultrastructural studies, lipidic inclusions in mitochondria were seen that were not observed in controls. It was speculated that mitochondrial dysfunction may be implicated in a failure of adenosine triphosphate-dependent axoplasmic transport in adrenomyeloneuropathy spinal tracts with a consequent`dyingback' axonal degeneration. The authors went on to discuss that with a lack of neuronal loss, there may be present a window of therapeutic opportunity. However, whereas sensory symptoms may be problematical in adrenomyeloneuropathy, the majority of the disability results from spasticity, and it is unclear at present whether motor neurons are spared suf®ciently to allow treatment.
Conclusion
Peroxisomal disorders continue to contribute to the understanding of organelle assembly and protein importation. It is apparent that the peroxisomal mechanism is different from other subcellular components, and further understanding will come from the appropriate studies of affected patients. In both peroxisomal assembly disorders and the single enzyme group, the neurological manifestations are varied, affecting different areas of the nervous system and at different times. This is no more apparent than in adrenoleukodystrophy, but the natural history and pathogenesis of this condition are gradually being elucidated. Although effective therapy remains an elusive goal, knowledge about the pathogenesis will hopefully contribute to this end.
